Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexlansoprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 4/20 | 0.61 |
| ▸ | ATP4B known ✓ | P51164 | 4/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | WDR5 | P61964 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | ENGASE | Q8NFI3 | 3/20 | 0.61 |
| ▸ | SARM1 | Q6SZW1 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | ATP1A1 | P05023 | 3/20 | 0.61 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.61 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.61 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.61 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexlansoprazole SCHEMBL29950208 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL29353881 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL29353345 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL29598842 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL8597994 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL22366 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL29358567 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL29750802 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL1559598 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL22365 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 536 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109912683-A | Cytotoxin molecule, conjugate, preparation method and application thereof | 杭州多禧生物科技有限公司 | 2019-06-21 | — | — | CN | claimed |
| EP-2262790-B1 | CRYSTAL OF BENZIMIDAZOLE COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-06-07 | — | — | EP | claimed |
| US-9145389-B2 | Benzimidazole compound crystal | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-29 | — | — | US | claimed |
| US-20150025115-A1 | BENZIMIDAZOLE COMPOUND CRYSTAL | TAKEDA PHARMACEUTICAL (JP) | 2015-01-22 | — | — | US | claimed |
| US-8884019-B2 | Benzimidazole compound crystal | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-11 | — | — | US | claimed |
| EP-2281821-B1 | Process for producing a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole | TAKEDA PHARMACEUTICAL (JP) | 2014-10-22 | — | — | EP | claimed |
| US-20140012006-A1 | BENZIMIDAZOLE COMPOUND CRYSTAL | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-09 | — | — | US | claimed |
| US-20130281704-A1 | SALTS OF BENZIMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2013-10-24 | — | — | US | claimed |
| US-8552198-B2 | Benzimidazole compound crystal | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-08 | — | — | US | claimed |
| WO-2013140120-A1 | GLYCEROL SOLVATE FORMS OF (R) - 2 - [ [ [3 -METHYL -4 (2,2, 2 - TRIFLUOROETHOXY) PYRIDIN- 2 - YL] METHYL] SULPHINYL] - 1H - BEN ZIMIDAZOLE | CIPLA LIMITED (IN) | 2013-09-26 | — | — | WO | claimed |
| US-20030153766-A1 | Process for producing crystal | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-08-14 | — | — | US | claimed |
| CN-1117747-C | Preparation method of optical purity lansoprazole | CHENGDU ORGANIC CHEM INST (CN) | 2003-08-13 | — | — | CN | claimed |
| EP-1306375-A1 | SALTS OF BENZIMIDAZOLE COMPOUND AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-05-02 | — | — | EP | claimed |
| EP-1293507-A1 | PROCESS FOR PRODUCING CRYSTAL | Takeda Chemical Industries, Ltd. (JP) | 2003-03-19 | — | — | EP | claimed |
| US-20030045724-A1 | Antiulcer agent | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2003-03-06 | — | — | US | claimed |
| US-6462058-B1 | R-2-(((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL) -METHYL)SULFINYL)-1 H-BENZIMIDAZOLE OR R-LANSOPRAZOLE; STABLE AND ABSORBABLE ANTIULCER AGENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-10-08 | — | — | US | claimed |
| WO-2002044167-A1 | PROCESS FOR THE CRYSTALLIZATION OF (R)- OR (S)-LANSOPRAZOLE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-06 | — | — | WO | claimed |
| CN-1329003-A | Preparation method of optical purity lansoprazole | CHENGDU ORGANIC CHEM INST (CN) | 2002-01-02 | — | — | CN | claimed |
| EP-1129088-A2 | CRYSTALLINE FORM OF (R)-2-[[[3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)-2-PYRIDINYL]METHYL]SULFINYL]-1H-BENZIMIDAZOLE | Takeda Chemical Industries, Ltd. (JP) | 2001-09-05 | — | — | EP | claimed |
| WO-2000078745-A2 | CRYSTALLINE FORM OF (R)-2-[[[3-METHYL- 4- (2,2,2,- TRIFLUOROETHOXY) -2- PYRIDINYL] METHYL] SULFINYL] -1H-BENZIMIDAZOLE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-12-28 | — | — | WO | claimed |